Recently, an increasing number of studies have demonstrated the potential of using BRMS1 as a prognostic marker and therapeutic target for breast cancer (27), ovarian cancer (4), melanoma (11) and NSCLC (26). This evidence concerns the gene BRMS1 and melanoma.